Last reviewed · How we verify
BL-M09D1
At a glance
| Generic name | BL-M09D1 |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (PHASE1)
- A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BL-M09D1 CI brief — competitive landscape report
- BL-M09D1 updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI